


BioPharmaceuticals

Annual Report 2023 Fact Sheet

Our ambition is to transform care for billions of people living with chronic diseases and deliver long-lasting immunity.

We are working to intervene earlier to protect vital organs, slow or reverse disease progression, and achieve remission for often degenerative, debilitating and life-threatening conditions, so many more people can live better, healthier lives.

3 key markets




Cardiovascular, Renal & Metabolism

Our ambition is to improve care to save lives for the millions living with cardiovascular, renal and metabolic (CVRM) diseases, stop disease progression and, ultimately, pave the way to a cure.

Therapy area world market
(MAT Q3-23)

\$286.1bn

Annual worldwide market value



- Diabetes **\$159.3bn**
- High blood pressure **\$37.1bn**
- Abnormal levels of blood cholesterol **\$19.2bn**
- Thrombosis **\$6.9bn**
- CKD **\$9.4bn**
- CKD-associated anaemia **\$5.3bn**
- Hyperkalaemia **\$0.9bn**
- Other CV **\$58.0bn**

Source: IQVIA.

AstraZeneca focuses on specific segments within this overall therapy area market. Sales for CKD (\$9.4bn) and CKD-associated anaemia (\$5.3bn) fall outside the CVRM total market. All sales for CKD-associated anaemia (\$5.3bn) fall within the CKD market and should not be double counted.

Total Revenue

\$10,628m

up 15%

(18% at CER)

Unmet medical need and AstraZeneca in 2023

20m

deaths per year are due to CVRM diseases.

4 out of 10

top causes of death globally are due to CVRM diseases.

One third

Cardiovascular disease (CV) is the leading cause of death and is responsible for approximately one third of all deaths globally.

850m

Nearly 850 million people worldwide, or more than one in 10 people, are affected by kidney disease and more than 90% of people with CKD remain undiagnosed. Our ambition in CKD is to eliminate progression to kidney failure.

64m

Heart failure (HF) affects nearly 64 million people globally and is closely linked to other CVRM conditions. Our ambition is to eliminate HF as first cause of hospitalisation and cure HF with reduced ejection fraction.

>650m

More than 650 million adults are living with obesity and the prevalence of diabetes is expected to rise to 783 million by 2045. Our ambition is to eliminate metabolic dysfunction-associated steatohepatitis, (MASH, previously NASH) fibrosis as a leading cause of liver failure. We also remain committed to treat beyond haemoglobin A1C in T2D.


Respiratory & Immunology

Our ambition is to transform respiratory and immunology care for patients, moving beyond symptom control to disease modification, remission and, one day, cure.

Therapy area world market
(MAT Q3-23)

\$88.8bn

Annual worldwide market value



- Asthma \$25.0bn
- COPD \$17.4bn
- Other \$46.3bn

Source: IQVIA.

AstraZeneca focuses on specific segments within this overall therapy area market.

Total Revenue

\$6,404m

up 7%

(10% at CER)

Unmet medical need and AstraZeneca in 2023

>40m

people worldwide have the immune-mediated diseases we are targeting, which carry a high disease burden.

3rd

Chronic obstructive pulmonary disease (COPD) is the world's third leading cause of death.



COPD

We are working to eliminate COPD as a leading cause of death by transforming care through our broad portfolio.

Asthma

Our ambition in asthma is to eliminate asthma attacks and achieve clinical remission, even in people with the most severe asthma.

Immunology

Our ambition is to disrupt immunology by focusing on areas of high unmet medical need to drive clinical remission and eventually cure.

New Respiratory

We are also moving beyond asthma and COPD to address other respiratory diseases with significant unmet medical need, including severe viral lung infection, interstitial lung disease and idiopathic pulmonary fibrosis (IPF).

Vaccines & Immune Therapies

Our ambition is to develop and deliver transformative vaccines and antibodies, providing long-lasting immunity to millions, and supporting sustainable and resilient healthcare systems worldwide by reducing the burden of frequent infectious diseases.

Therapy area world market
(MAT Q3-22)

\$12.3bn

Annual worldwide market value

Source: IQVIA.

AstraZeneca focuses on specific segments within this overall therapy area market.

Total Revenue

\$1,357m

down 72%

(71% at CER)

Unmet medical need and AstraZeneca in 2023

Up to 4%

of the population is immunocompromised and is at a higher risk of hospitalisation from COVID-19 than the general population.

One billion

Globally there are one billion cases of seasonal influenza annually.

Vaccines

We are engineering next-generation vaccines that have the potential to generate potent and long-lasting immune responses.

Antibodies

We are pioneering novel approaches to develop highly targeted, long-acting antibodies, using our half-life extension technology.